Skip to main content
Vita 34 AG logo

Vita 34 AG — Investor Relations & Filings

Ticker · V3V ISIN · DE000A0BL849 LEI · 529900OEWA4GSZEZ4P40 F Human health and social work activities
Open in API
Filings indexed 794 across all filing types
Latest filing 2019-03-21 Report Publication Anno…
Country DE Germany
Listing F V3V

About Vita 34 AG

https://www.vita34.de/en/

Vita 34 AG is a biobank specializing in the cryopreservation of stem cells derived from umbilical cord blood and tissue. Established in 1997 as the first private cord blood bank in Europe, the company offers services for the long-term storage of perinatal stem cells for potential future medical applications. The service portfolio includes providing collection kits for childbirth, handling logistics, processing the biological material, and storing the stem cell deposits under cryogenic conditions. These services are offered to expectant parents as a form of private medical provision for their child and family. As part of the Famicord Group, Vita 34 is also involved in research and development related to cell-based therapies.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2019
Report Publication Announcement Classification · 100% confidence The document is a short announcement dated March 21, 2019, titled "Vita 34 AG: Preliminary announcement of the publication of financial reports...". It explicitly states that the Annual financial report and the Annual financial report of the group will be disclosed on March 28, 2019, and provides links to where these reports will be available. According to Rule #2 (The "MENU VS MEAL" Rule), a short document announcing the future publication of a report should be classified as a Report Publication Announcement (RPA), not the report itself (like 10-K or IR).
2019-03-21 English
Hinweis auf Jahresfinanzbericht vom 01.01.2018 bis zum 31.12.2018
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 800 characters) informing shareholders that the Annual Financial Report for the period 01.01.2018 to 31.12.2018 is available on the company's website. It does not contain the report itself, but rather acts as a formal announcement of its publication. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2019-03-21 German
Datum:21.03.2019
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 1,000 characters) that informs shareholders about the availability of the annual financial report for the period 01.01.2018 to 31.12.2018. It provides a link to the website where the report can be accessed rather than containing the report itself. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2019-03-21 German
Vita 34 concludes 2018 with significant earnings growth according to preliminary figures
Earnings Release Classification · 100% confidence The document is titled 'Vita 34 concludes 2018 with significant earnings growth according to preliminary figures' and explicitly states it is based on 'preliminary unaudited financial figures'. It provides key financial metrics (Revenues, EBITDA) for the full year 2018 and compares them to 2017. This content structure—a brief announcement highlighting key preliminary financial results for a period—is characteristic of an Earnings Release (ER). It is not the full Annual Report (10-K) because it explicitly states the full Annual Report will be published later (on 28 March 2019). It is also not a Call Transcript (CT) or an Investor Presentation (IP). FY 2018
2019-02-28 English
Vita 34 develops cell preparations as the source material for immune cell therapies and becomes cell bank
Regulatory Filings Classification · 100% confidence The document is a news release dated February 8, 2019, originating from Vita 34 AG, disseminated via DGAP (a service often used for regulatory news). The content describes a strategic business decision: expanding from a stem cell bank to a broader 'cell bank' offering cryopreservation of immune cells. It discusses future plans, market potential, and management commentary. This type of announcement, detailing strategic corporate changes and business development rather than specific financial results (ER/IR), board changes (MANG), or shareholder votes (DVA), fits best under a general regulatory announcement or news release category. Since it is a significant corporate update that doesn't perfectly match the highly specific categories like M&A (TAR) or Capital Change (CAP), and it is not a full report (10-K/IR), the most appropriate classification is Regulatory Filings (RNS) as a general corporate news item disseminated through official channels.
2019-02-08 English
Vita 34 records increasing number of uses of umbilical cord blood
Regulatory Filings Classification · 99% confidence The document is a short news release dated December 12, 2018, disseminated via DGAP (a service often used for regulatory news). It announces a specific operational update: Vita 34 AG recording an increasing number of uses of umbilical cord blood, citing clinical studies and future expectations. This is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a formal proxy/voting document. It is a general corporate announcement regarding business activity that doesn't fit the specific categories like M&A, Capital Change, or Director's Dealing. Given its nature as a timely, non-financial-statement-focused update distributed through a regulatory news service, it best fits the general 'Regulatory Filings' fallback category (RNS), as it is a general corporate news item transmitted via a service that handles regulatory announcements.
2018-12-12 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.